Leronlimab blocks the CCR5 receptor.
The Synergy: While TAS-102 kills the cells and bevacizumab cuts off the food supply, leronlimab stops the survivors from running away (metastasizing) and prevents the "bodyguard" immune cells from protecting the tumor.
They need a GATEKEEPER!